Online inquiry

IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12096MR)

This product GTTS-WQ12096MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12096MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11680MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ14664MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ7343MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ3873MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ6395MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ13413MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ3318MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ6996MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW